ExThera Medical Corporation
ExThera Medical develops and commercializes extracorporeal blood filtration devices, including the Seraph 100 Microbind Affinity Blood Filter and ONCObind, for removing harmful substances from the bloodstream. The company aims to serve healthcare professionals and patients worldwide, with a focus on treating severe infections, sepsis, COVID-19, and metastatic cancer. Their products have demonstrated life-saving capabilities and are involved in clinical trials and regulatory processes to expand their indications.
Industries
Nr. of Employees
small (1-50)
ExThera Medical Corporation
Martinez, California, United States, North America
Products
Affinity-based hemoperfusion blood filter
Disposable extracorporeal blood filter employing affinity adsorption media to bind and remove pathogens, circulating tumor cells and sepsis mediators from whole blood during extracorporeal circulation.
Oncology-focused hemoperfusion procedure (investigational)
Investigational extracorporeal hemoperfusion procedure using affinity adsorption media to capture and reduce circulating tumor cells as an adjunct to cancer therapy; studied under feasibility and investigational device protocols.
Affinity-based hemoperfusion blood filter
Disposable extracorporeal blood filter employing affinity adsorption media to bind and remove pathogens, circulating tumor cells and sepsis mediators from whole blood during extracorporeal circulation.
Oncology-focused hemoperfusion procedure (investigational)
Investigational extracorporeal hemoperfusion procedure using affinity adsorption media to capture and reduce circulating tumor cells as an adjunct to cancer therapy; studied under feasibility and investigational device protocols.
Services
Sponsorship and conduct of multicenter clinical trials and registries
Design, sponsorship and operational support for randomized controlled trials, observational registries and feasibility studies evaluating extracorporeal blood purification therapies.
Commercial distribution partnerships
Establishment of regional distribution and co-marketing agreements to enable device supply and clinical adoption in target markets.
Sponsorship and conduct of multicenter clinical trials and registries
Design, sponsorship and operational support for randomized controlled trials, observational registries and feasibility studies evaluating extracorporeal blood purification therapies.
Commercial distribution partnerships
Establishment of regional distribution and co-marketing agreements to enable device supply and clinical adoption in target markets.
Expertise Areas
- Extracorporeal blood purification
- Sepsis and bloodstream infection management
- Adjunctive oncology approaches targeting circulating tumor cells
- Clinical trial design and multicenter trial operations
Key Technologies
- Hemoperfusion / extracorporeal blood purification
- Affinity adsorption microbeads with immobilized heparin
- Hemoadsorption media for pathogen and circulating tumor cell capture
- Integration with extracorporeal circuits (dialysis, ECMO)